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Abstract
It is widely accepted that the (now reversed) Bush administration’s decision to restrict federal funding for human embryonic
stem cell (hESC) research to a few ‘‘eligible’’ hESC lines is responsible for the sustained preferential use of a small subset of
hESC lines (principally the H1 and H9 lines) in basic and preclinical research. Yet, international hESC usage patterns, in both
permissive and restrictive political environments, do not correlate with a specific type of stem cell policy. Here we
conducted a descriptive analysis of hESC line usage and compared the ability of policy-driven processes and collaborative
processes inherent to biomedical research to recapitulate global hESC usage patterns. We find that current global hESC
usage can be modelled as a cumulative advantage process, independent of restrictive or permissive policy influence,
suggesting a primarily innovation-driven (rather than policy-driven) mechanism underlying human pluripotent stem cell
usage in preclinical research.
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Introduction
Human embryonic stem cells (hESCs) have attracted much
research attention over the last 15 year. Despite of the existence
of a steadily increasing number of hESC lines, several studies
have noted a preferential use of only a few lines (particularly the
WiCell lines derived by Thomson and colleagues in 1998 [1]) in
the vast majority of hESC studies, both within the United States
(US) and throughout the rest of the world [2–6], although
regional differences in stem cell usage patterns have been
reported [5].
In 2001 the Bush administration decided to restrict federal
funding through the National Institutes of Health (NIH) to
research using hESC lines derived prior to August 9th of that year
(there are 21 such lines; we will refer to them as ‘‘formerly NIH
approved hESC lines’’). This policy decision has stirred much
controversy [7,8] and has been perceived as providing a long-
lasting impediment for competitive hESC research in the US by
providing a restrictive bias towards the use of formerly NIH
approved cell lines [9–11]. Although President Obama lifted the
Bush administration’s restrictive policy in 2009 [12] (and despite
the fact that several-state run research programs have been created
in the last decade to facilitate more diverse hESC research [13]),
the on-going preferential use of a subset of the Bush-approved cell
lines has also primarily been attributed to the NIH’s funding
policy.
However, the scientific basis for these claims remains obscure
[3,4,6,14]. In particular, the policy-driven model does not
adequately explain the preferential usage of a small subset of the
formerly NIH-approved hESC lines (particularly, WiCell’s H1 and
H9 lines); nor does it adequately account for the similar hESC
usage patterns observed in countries with different (including
diametrically opposing) stem cell usage policies. Motivated by
these apparent inconsistencies, we set out to understand the
generative mechanisms underlying global hESC usage.
We analysed more than 2,300 peer-reviewed studies that
documented the experimental use of identifiable hESC lines.
Thus, we chose to study the actual use of hESC lines in successfully
completed basic and preclinical research projects. This is in
contrast to other studies, which have considered a variety of
proxies for actual hESC usage including: material transfer
agreements on shipping of cell lines from selected providers
[3,4]; preliminary results presented at a single conference [6]; data
on the intended hESC usage in grant applications [13,15]; and
information obtained from surveying stem cell scientists in the US
[16,17]. Analysis of our data indicated a striking heavy-tailed
distribution of hESC usage, as has been previously observed [16],
with most studies only making use of a small number of hESC lines
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(Fig. 1A). To interpret this data we compared the ability of a
policy-driven model and a simple cumulative-advantage model,
based upon dissemination of cell lines within an evolving scientific
collaboration network, to explain hESC usage. We find that
current hESC usage patterns can be easily and more precisely
explained by a policy-independent model.
Materials and Methods
Literature Search
Database searches for hESC research papers were performed as
previously reported [5]. Our initial search resulted in more than
11,000 hits for papers listed in the PubMed database and
published in peer-reviewed English language journals through
the end of 2011. Criteria for paper extraction as well as for
assignment of papers to specific countries are reported elsewhere
[5]. Briefly, papers were manually evaluated to exclude those
manuscripts in which hESCs were not used experimentally (e.g.
commentaries, reviews, news, and editorial articles; work on
mouse embryonic stem cells or human embryonic carcinoma cells;
papers on ethical or political aspects of hESC research etc.).
Articles that summarized previously described methods and
protocols as well as those in which only hESC-derived materials
(but not hESCs themselves) were used were also excluded. In total
we found 2,403 primary research articles that reported the
derivation and/or experimental use of hESCs. Of these 2,403
original research papers, 65 (2.7%) did not contain sufficient
details concerning the specific hESC cell lines to be used and were
therefore also excluded from further analysis. In total we therefore
considered data from 2,338 unique research articles. A number of
Figure 1. Analysis of the hESC co-citation network. (A) Frequency distribution for hESC line use based on the evaluation of 2,338 studies
reporting original research involving hESCs and published in peer-reviewed English language journals from 1998 to 2011. The inset highlights the 40
most used lines. Asterisks denote those hESC lines available and eligible for federal funding under the Bush administration from Aug. 9, 2001 to Mar.
9, 2009. Note that in most papers several hESC lines were used. (B) The largest connected network of the empirical hESC co-citation network. Peer
reviewed studies involving experiments with identifiable hESC lines published from 1998 to 2011 are represented as boxes; hESC lines are
represented as circles (see Fig. S2 for the entire network, including all disconnected components). The network is dominated by few lines (H1, H7,
H9, HES-2, HES-3, BG01), which were introduced early in the stem cell field. (C) Correlation of hESC usage with time of derivation. Lines derived earlier
are used more frequently than those lines derived later, a pattern that appears to be independent of policy influence. Error bars: standard deviation of
mean.
doi:10.1371/journal.pone.0052068.g001
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primary cell lines (such as H9, H1, AS034 and HES-3) were
represented by several secondary sub-lines [e.g. H9.1, H9.2, H1.1,
H1-OGN, AS034.1, HES-3.gfp (ENVY)]. These secondary sub-
lines were collapsed into the parental lines (e.g. H9.1, H9.2 etc.
were all considered H9). Funding information was retrieved from
the appropriate sections in the paper text.
Database searches for papers reporting derivation and exper-
imental use of human induced pluripotent stem cells (hiPSCs) were
performed according to reference [18] and resulted in a set of 514
research papers published through the end of 2011. Criteria for
inclusion of a paper were basically the same as for hESC research
papers.
Assignment of papers to specific countries was performed
according to the academic affiliation of the corresponding author.
A detailed paper list is available on request.
Network Simulation
We compared our empirical findings with simulations of a Yule-
Simon process [19,20]: a model commonly used for simulations of
social networks. We adapted the original Yule-Simon process
[19,20] using a procedure proposed by Morris for bipartite graphs
[21].
In our simulations we assumed that all studies use the same
number of hESC lines (N = 2). We selected this parameter since it
is close to the observed mean number of cell lines used per study in
the main connected component of the empirical hESC usage
network (in the empirical network, the mean number of lines used
per publication is 2.47). To compensate for these minor differences
we increased the number of studies in our simulation to 2,927 to
arrive at the same overall number of citations.
In our simulations (see Fig. 2B), when a new stem cell study is
started, we decide how many novel hESC lines are introduced
based on a binomial probability of success in N independent draws
with an associated probability p. The newly generated stem cell
study is then added to the stem cell research network. If a study
does not use a novel line, then the lines employed in the study are
chosen from the preexisting cell lines already in use. We took the
probability of selecting an individual line from the pool of
preexisting hESC lines to be proportional to the number of times
each cell line has been previously used in other studies. To
estimate the probability with which a novel line is chosen, we ran
our model with probabilities of 0.05, 0.1, 0.15, 0.2, 0.25 and 0.3
for introducing a new hESC line into the simulated network. We
selected a probability of 0.15 based on comparison with the
empirical dataset. The resulting networks are directed bipartite
graphs, which are not necessarily connected. In order to obtain
statistics of usage we generated 1,000 random simulated instances
of our model.
We used the power.law.fit method from the igraph package with
xmin = 3 to estimate the exponent for the in-degree distribution of
the network [22]. Although we find a good fit we caution that our
empirical hESC co-citation network only contains 2,338 nodes,
which is relatively small for reliable direct parameter estimation.
Direct methods for determining fit to power-laws usually require
datasets with several orders of magnitude more observations; we
refer the reader to Clauset and Newman [23,24] for a
comprehensive discussion of the challenges and methods involved
in estimating power-law distributions from empirical data. The R
script of our simulation implementation is available on request.
Network Analysis
We first analyzed the connected components of the networks.
The biggest component contains the largest number of publica-
tions. We found the remaining components were dominated by
cell lines that were used only in a single study and often appeared
in manuscripts that reported the derivation of a large number of
new hESC lines. We conclude that the biggest component reflects
most hESC research activity. Empirical network analysis and
visualization was performed in R as in reference [25] using the
igraph [22] package. Additional plots were generated with
Cytoscape [26].
Hierarchical Clustering
cluster global usage we selected only those countries with at least
30 publications to avoid spurious effects due to small sample sizes.
The distances between the 14 identified countries were calculated
as one minus the Spearman correlation of the hESC usage
patterns. Hierarchical clustering was then performed in Matlab
(Mathworks, Natick, MA, USA) using average linkage. The
assignment of a nationality to study was based on the affiliation
of the corresponding author.
Stem Cell Usage and Time of First Publication
For each cell line, the number of studies it was used in and the
year of first publication were determined. A linear regression
model using the year of first publication as the independent
variable and the logarithm of usage frequency as the dependent
variable was calculated using robust linear regression in R using
the MASS package [27]. The resulting regression model was used
to predict the year of first publication depending on the frequency
of usage (Fig. 2C). The z-score was calculated based on the mean
and standard deviation of all cell lines that were first published in
the same year.
Results
We first analysed the usage of hESC lines in 2,338 peer-
reviewed studies that reported original experimental research
using identifiable hESC lines published worldwide through the end
of 2011. This data confirmed the continuing preferential use of a
few prominent hESC lines derived early in the history of the field
(Fig. 1A and B). This is in agreement with previous observations
made by us and other groups [2–6,13,15], and occurs despite the
existence of a considerable and diverse library of more than 1,000
hESC lines (as of the end of 2009) for the research community to
use [5]. We note that even among the 21 former eligible lines – of
which 18 were distributed by the same stem cell bank – usage
frequency varies considerably (from H9 used in 996 studies; to I4
used in 8 studies, Fig. 1A).
We found no correlation between national hESC policy (i.e.
restrictive versus permissive) and the use of specific hESC lines
(Fig. S1). Rather, we found that hESC use correlates strongly
with year of derivation (Fig. 1C). Furthermore, we observed that
the frequency distribution for hESC use could be approximated by
a power-law (Fig. 1A). Power-law like distributions of influence
have been observed in many complex systems, particularly in
citation and social networks [23,28]. In these networks, power-law
like distributions are often assumed to result from an underlying
generative mechanism that has been termed in different contexts a
Matthew effect, Yule process, cumulative advantage or preferential attachment
[23,28]. In this model, a small number of initial ‘‘founder’’ nodes
gain a disproportionate share of the interactions in the network
through a ‘‘rich-get-richer’’ process as the network grows.
Given these parallels we asked whether similar mathematical
models could equally well explain why specific subsets of hESC
lines are used preferentially in the US and worldwide. We
hypothesized that the emergence of the observed distribution of
hESC usage, skewed towards the frequent use of only very few cell
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lines derived early on, could be modelled as a cumulative
advantage process without the need for additional mechanisms
such as the influence of funding policies or legal restrictions.
To do this we constructed a simple mathematical model
(outlined schematically in Fig. 2A) based on the assumption that
published peer-reviewed experimental studies involving hESC
lines accurately serve as a surrogate to assess the use of hESC lines
in specific hESC research projects. To start the model we assumed
that a few founder lines are generated in a first project and were
made available to a broader research community (as is the case for
Figure 2. A cumulative advantage model for global hESC usage patterns. (A) Schematic of our simple cumulative advantage model. (B) The
observed cumulative frequency distribution of hESC usage is in red; 1000 simulations of the model outlined in (A) are shown in grey. For illustrative
purposes, the best fit of the model to the data is shown in black. (C) Policy-independent assumptions allow for the statistical detection of
‘‘anomalous’’ lines in the empirical data (all lines represented by circles). A predicted distribution year for each of the published 995 cell lines, based
on their usage patterns, was computed and the predicted year was compared with the actual first publication year. A predicted distribution date
strikingly earlier than the actual publication date indicates that a published line is more widely used than would be expected by comparison with
those lines published around the same time. The green line separates from the bulk population those lines with a predicted distribution date at least
4 years earlier than their actual publication date. Seven hESC lines (z-scores in red) appear to have been distributed at least four years earlier than
their actual publication date. Five of these lines (BG01, HSF6, CA1, KhES-3 and HS401; shown in grey) were in fact derived and distributed significantly
before their first peer reviewed publication date (see Table S4). Lines used significantly more often than others published in the same year (z-score
.2) are indicated in red. (D) Possible technological explanations for the observed unusual usage patterns of hESC lines HUES9 and WIBR3.
doi:10.1371/journal.pone.0052068.g002
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hESC research) [1]. Next we assumed that new hESC studies are
performed over time, with each new study using two distinct hESC
lines (this is in agreement with the observed empirical average of
2.47 hESC lines per study, see Materials and Methods). In each
new study, we assumed that new hESC lines are derived with
probability p or, alternatively, pre-existing lines are used with a
probability 1-p. In accordance with a cumulative advantage
process we assumed that the probability of selecting an individual
pre-existing hESC line is proportional to the number of pre-
existing studies already using that line. This is plausible since stem
cell lines with efficient distribution channels; those which already
exist in the freezers of a research institution; or those for which
there is a wealth of experience and published data are likely to be
preferentially chosen when planning new experiments. This simple
model results in simulations of a growing hESC usage network.
This network is a bipartite graph with stem cell lines and published
studies as nodes, in which there is an edge between a cell line and a
study if the study uses that cell line. The frequency distribution for
the use of hESCs in research may then be obtained by counting
the number of edges between publications and cell lines. Crucially,
in this model, the current status of hESC usage is dependent upon
the history of hESC usage. Particularly this model strongly favours
hESC lines that were introduced early (a phenomenon known as
the ‘‘first mover advantage’’ in scientific co-citation networks)
[24,29] (Fig. S3C). It should be pointed out that our model does
not contain a discernible ‘‘policy term’’, which could be
interpreted as governmental ‘‘power’’ driving stem cell research
through laws or regulations towards the usage of only few
‘‘eligible’’ lines.
To compare empirical data with our model we also generated
an empirical hESC usage network. As with the simulated
networks, this network is a bipartite graph with stem cell lines
and published studies as nodes, in which there is an edge between
a cell line and a study if the study uses that cell line. (Fig. 1B, Fig.
S2). We find that our cumulative advantage model (Fig. 2A)
resulted in simulated networks strikingly similar to the observed
empirical hESC usage network (Fig. 2B, Fig. S3).
To further analyse at least anecdotal evidence for a policy-
driven model, we examined the interesting case of the California
Institute for Regenerative Medicine (CIRM): a multi-billion dollar
research organisation established, in part, to counteract the
possibly negative effects of political funding restrictions, and
enable California-based researchers to derive and use cell lines
other than those eligible for NIH funding during the Bush
presidency [30,31]. We reasoned that, assuming a policy-driven
model, one would expect at least a trend towards the increased use
of those hESC lines not eligible for NIH funding in CIRM-
associated publications. However, we found that of 185 hESC
studies bankrolled at least in part by CIRM and published from
2008 to 2011, 171 (92.4%) used prominent formerly NIH
approved hESC lines introduced early in the field (Table S1).
While 28 (15.1%) used other hESC lines in addition to formerly
NIH approved lines, 143 CIRM-funded studies (77.3%) were
exclusively based on formerly NIH approved hESC lines. Only 14
studies (7.6%) were performed without use of any formerly NIH
approved hESC lines. Since 110 of the 185 CIRM-funded studies
were also supported by NIH grants, we investigated more closely
those 75 CIRM funded studies that were performed without
additional NIH funding. In 63 (84%) of these studies, at least one
formerly NIH approved hESC line was used, and in 50 studies
(66.7%) formerly NIH approved hESC lines were used exclusively.
Only 12 studies (16%) were performed without the use of any
formerly NIH approved hESC line. This is in accordance with
recent analyses of state-funded stem cell research grants, including
those from CIRM, which have suggested a similar preference for
formerly NIH approved lines at the grant application stage of the
research process [13,15]. We also observed a comparable pattern
of hESC line usage in studies from Germany after strict
regulations, similar to those in the US, were significantly lifted in
2008 (Table S2).
To investigate this further we performed a hypergeometric test
to determine if there are any statistically significant differences in
use of formerly NIH-approved hESC lines in CIRM-funded,
NIH-funded and worldwide studies. We found that in both the US
and worldwide there was a significant preference for the use of
early derived formerly NIH approved lines (Fig. 3, Table S3).
This was also true for CIRM funded studies, despite independent
funding. These results indicate a firm attachment to early hESC
lines, particularly those derived in the US by Thomson and
colleagues in 1998 [1].
To investigate further if stem cell usage might be more
independent of policy decisions than widely assumed, we
investigated cell line usage in the rapidly developing, and far less
regulated, field of human induced pluripotent stem cell (hiPSC)
research. Thomson et al. [32], Yamanaka et al. [33,34] and Daley
et al. [35] derived the first hiPSC lines in 2007. hiPSCs are widely
believed to represent a seminal breakthrough in stem cell research
[36]. Although there are still open questions regarding qualitative
differences between hiPSCs and hESCs [37], they potentially
provide an inexpensive, robust and ethically less controversial
means to derive patient-matched human pluripotent cells. Among
the 512 original research papers involving hiPSCs published from
2008 through the end of 2011 we identified 201 manuscripts that
used previously established hiPSC lines in which the lab of origin is
clearly specified. Due to lack of a consistently used cell line
nomenclature, it is very difficult to reliably track the use of
individual hiPSC lines [38]. Thus, we used the lab provenance as a
proxy measure for actual hiPSC usage. Of the aforementioned 201
studies, 54 (26.9%) used hiPSC lines reported by the Thomson lab
in 2007 [32], 29 (14.4%) used cell lines reported by Yamanaka and
colleagues [33,34] and 28 (13.9%) used hiPSCs developed by
Daley and co-workers [35]. The tendency to the preferred usage of
only few hiPSC cell lines is not as pronounced as in the case of
hESCs. hiPSCs are more easily derived than hESCs and many
groups have produced their own hiPSC lines for use in multiple
studies. Nevertheless, the share of papers using those first hiPSC
cell lines published in 2007 increases to about 70% if only those 93
studies in which investigators did not possess their own hiPSCs
(but exclusively used lines derived in other laboratories) are taken
into account. The fact that early hiPSC lines derived in only three
labs are employed in more than 50% of hiPSC studies using
previously established lines suggests that a first-mover effect may
also be an emerging property in the hiPSC research field.
We finally asked if our cumulative advantage model could be
useful for identifying emerging hESC usage trends from empirical
data. To do this we fitted a regression model to the observed hESC
usage distribution in order to compare actual hESC first
publication dates with predicted hESC distribution dates based
solely on observed usage frequencies per year. We combined this
method with a z-score procedure previously proposed for the
identification of outliers (in our case, individual hESC lines) [24].
On the basis this analysis we tentatively predict that later
established yet highly utilized hESC lines, may have been widely
distributed before the date of their first publication (i.e. they are
‘‘older’’ than they appear) or, more interestingly, might be
technologically more relevant to future research than the
remaining bulk of hESC lines of comparable age. Using this
method we highlighted 7 widely used but later-derived hESC lines
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of interest, out of a total of 955 (Fig. 2 C and D, Table S4). Five
of these lines (BG01, HSF6, HS401, CA1, KhES-3) were indeed
derived and distributed significantly before their first peer
reviewed publication date (see Table S4). The remaining two
lines (HUES9 and WIBR3) illustrate two longstanding innovation
trends in hESC research: 1) the HUES9 line originates from the
Melton lab [39] and exemplifies the push towards diversifying
available hESC lines, and 2) the WIBR3 line examplifies ongoing
efforts to derive more naı̈ve hESC lines [40].
Discussion
In this study, we analysed human pluripotent stem cell usage
patterns by investigating a comprehensive dataset based on
published hESC research and proposed a simple mathematical
model that qualitatively explains hESC usage patterns. Our
analysis shows that a simple first-mover generative mechanism,
that does not rely on funding policy as a causative factor, can
naturally explain the observed dominance in use of a small
number of hESC lines. Although our analysis does not exclude the
influence of policy decisions on hESC usage, the results question
accepted wisdom connecting stem cell usage patterns exclusively to
US funding policies [3,4,6,14].
In agreement with a purely policy-driven interpretation of
hESC usage, our model favours a set of early ‘‘founder’’ hESC
lines. However, in our model preferential use of these lines is not
due to political restrictions but rather arises naturally due to
collaborative processes within the scientific community. We argue
that if hESC use is a purely policy-driven process then qualitatively
different patterns of usage of ‘‘approved’’ and ‘‘restricted’’ cell lines
should be apparent in differing political environments. However,
when analysing worldwide usage patterns we observed no such
distinctions (Fig. 1A and B), suggesting that alternative under-
lying generative mechanisms significantly contribute to observed
hESC usage patterns.
Figure 3. Worldwide usage patterns of hESC lines. Changes over time in the number of studies using eligible (formerly NIH approved) and
non-eligible hESC lines is shown. Panel (A) shows global patterns; (B) patterns in the US and; (C) patterns in CIRM funded studies. Although the Bush
administration’s restrictions on hESC usage were lifted in March 2009 the number of publications exclusively using formerly restricted lines did not
increase significantly in any region from 2009–2011. For a detailed statistical comparison of these data see Table S3.
doi:10.1371/journal.pone.0052068.g003
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Several issues are associated with fitting power laws to empirical
datasets (particularly those with relatively small statistical support)
and the cumulative advantage process used here is only one of
several possible models that could have been applied [41].
Consequently, we caution that our proposed model may represent
just one possible alternative to a policy-driven interpretation of
hESC usage patterns: rejecting one hypothesis over another in a
complex process such as global hESC research is difficult on
purely statistical grounds, particularly using data from a relatively
small sample of 2,338 publications. Nevertheless, our model
indicates that disruptive innovation (i.e. breakthroughs which
fundamentally change the research landscape, such as the
derivation of the first hESC lines) and sustaining innovation (i.e.
refinements to existing hESC derivation and culture protocols)
may be primary drivers of worldwide hESC usage.
While much effort has led to improvements in hESC lines and
cultures since they were first derived by Thomson and colleagues
[1], their basic properties (i.e. self-renewal and multi-lineage
differentiation potential) remain unchanged, as do the challenges
(i.e. ethical problems) associated with their production. Even
though ethically less problematic lines from single blastomeres [42]
or biologically more naı̈ve hESC [40] have been subsequently
established, these lines have not been nearly so well used as the
earliest lines derived. By the end of 2009 publically available
information on more than 1,000 hESC lines was available from
the scientific literature, stem cell registries and banks, press releases
and institutional webpages [5]. Since then, the number of hESC
lines has further increased to nearly 1,600 as of July 2012. These
hESC lines have been derived for a number of reasons, including:
to better understand the derivation process, for example by
varying derivation conditions [43] or by using poor quality,
arrested or aneuploid embryos [44–46] as a source for hESCs; to
obtain cell lines with particular monogenetic disorders in order to
create disease-specific hESC based cell models [47]; and to obtain
clinical-grade hESC lines by performing derivation under xeno-
free conditions [48]. In a single study from China nearly 200
hESC lines were produced to match a broad panel of HLA
phenotypes [49]. Additionally, the prospect of creating ‘‘national’’
banks of hESC lines may also contribute to the drive to diversify
[50,51]. However, of the nearly 1,600 hESC lines publically
known by July 2012, about 500 have been not, as yet, been
reported in the scientific literature; while another approximately
650 have been used in only one report. The relevance of novel
hESC lines may therefore lie not in their frequency of use, but
rather in their value as assets in the clinical development portfolio
of organizations aiming at advancing hESC-based therapies (such
as CIRM and the NIH), as well as in the IP portfolio of
biotechnology companies such as Advanced Cell Technology Inc.
Our outlier analysis (Fig. 2C and D) indicates that technolog-
ical, sustaining innovation is a key driving-factor underlying the
derivation of such novel cell lines. The enormous resources and
investments that went into the development of clinical grade hESC
lines reveal a weakness of our (and others’) publication-based
analyses. On a global scale, development of such cell lines will
continue to merely increase the long tail of the observable hESC
usage distribution in spite of potentially low thresholds to access to
independent funding. Consequently, we predict that most basic
and preclinical research projects will continue to choose the most
frequently used and cited hESC lines as a starting point for their
research and clinical grade stem cell lines, such as HS401, will
remain under-utilized in preclinical hESC studies (although, in the
long-run the collection and dissemination of a wide panel of
reliable data for many hESC lines by stem cell registries and
banking initiatives [52–54] may contribute to the diversification of
hESC usage). It remains to be seen if such latter-derived (and
infrequently used) yet technologically innovative lines will
ultimately come to dominate clinical applications. The first
hESC-derived cells to be transplanted into a patient were
differentiated from the H1 hESC line [55], one of the first lines
reported by Thomson and co-workers in 1998 [1]. The H1 line is
also one of the two most widely used lines in the preclinical stem
cell field (Fig. 1) and is predicted by our model to remain so.
However, the same formerly NIH approved cell line received
much attention in 2006 as it was found to be contaminated with
the nonhuman sialic acid Neu5Gc in animal component derived
culture systems [56], although improved xeno-free culture
techniques have obviously rendered this technical problem
solvable for NIH approved clinical trials [55].
Taken together, our analyses question a substantial impact of
the Bush policy on use of specific hESC lines in basic and
preclinical research both globally and in the US. We conclude that
policy decisions concerning present and future funding for both
hESC and hiPSC research should account for alternative
generative mechanisms underlying human pluripotent stem cell
usage.
Supporting Information
Figure S1 Hierarchical clustering of global stem cell
usage patterns. Nations with at least 30 experimental hESC
publications were included in the analysis (AU: Australia, CA:
Canada, CN: China, DE: Germany, ES: Spain, FI: Finland, FR:
France, GB: United Kingdom, IL: Israel, JP: Japan, KR: South
Korea, SE: Sweden, SG: Singapore, US: United States of
America). Spearman rank correlation was used to assess similarity
in hESC usage patterns (see Materials and Methods). When
assigning a study to a country we used the institutional affiliation of
the corresponding author. Countries with diametrically opposing
policies on hESC use cluster together despite regulatory
differences. The policy classification for 2005 is according to
reference [57]; while that of 2012 was retrieved from http://
mbbnet.umn.edu. Note that the displayed policy classification is
only a relatively coarse-grained measure for complex national
hESC usage regulations.
(TIF)
Figure S2 Global hESC co-citation network. Full hESC
co-citation, including all peer-reviewed studies involving experi-
ments with identifiable hESC lines published from 1998 to 2011.
The network is a bipartite graph in which both hESC lines and
studies are drawn as circles. There is an edge between a cell line
and a study if the study uses that cell line. Most studies belong to
the largest connected component (in blue). Several considerably
smaller components (in orange) contain work with hESC lines that
rarely appear in other publications. The main component network
is displayed in more detail in Fig. 1B.
(TIF)
Figure S3 Observed and simulated network parame-
ters. We simulated a cumulative advantage process for the usage
of stem cell lines (as shown in Fig. 2B and described in the
Online Methods) 1,000 times and compared the parameter
distributions with the actual observed data points (marked red). (A)
Histogram of the distance (area enclosed between the curves)
between each simulation of our model and the empirically
observed stem cell usage data. The simulated result with the
smallest distance to the observed usage data is given in black in
Fig. 2B. (B) Histogram of estimated power law exponents for
each simulation of our model. The estimated empirical exponent
Power-Laws and Pluripotent Stem Cell Lines
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(1.94) is shown as a red line. (C) The frequency with which
‘‘founder’’ lines (the first 5 simulated lines in each simulation) and
subsequent lines were used in simulated networks. (D) Histogram
of the maximum number of citations received by a cell line in our
simulations (i.e. the maximum node degree in the final simulated
networks). The value observed for the empirical hESC co-citation
network (the H9 line which received 996 citations) is shown in red
line. (E) Histogram of the number of hESC lines in the largest
connected component of the simulated co-citation networks. The
value observed for the empirical hESC co-citation network (794) is
shown in red.
(TIF)
Table S1 Use of hESC lines in studies (co-)funded by the
California Institute for Regenerative Medicine. Statistics
of hESC use for all published hESC studies with CIRM-funding
(including those that also received additional funding from other
sources, e.g. from the NIH) are shown. CIRM funding started in
2006, so studies published from 2008 were investigated. Funding
information was taken from the appropriate section of the papers.
The percentage share in the total number of papers published is in
brackets. Note that more than one hESC line is used in most
studies; thus the percentages add up to more than 100.
(DOCX)
Table S2 Use of hESC lines in research papers from
Germany. Only cell lines that were used in at least two studies
are listed. Numbers in brackets indicate the percentage share of
the 56 hESC research papers from Germany published through
the end of 2011. Of all the hESC lines that became accessible to
German scientists after the amendment of the German Stem Cell
Act in 2008, only one (HUES2) was used in more than one
published study (note that prior to 2008 use of hESC lines in
Germany was restricted in principal to those lines formerly
approved by the NIH). In most studies more than one hESC line is
used; thus the percentages add up to more than 100.
(DOCX)
Table S3 Enrichment analysis for formerly NIH ap-
proved hESC lines. Statistically significant differences in use of
formerly NIH-approved hESC lines by comparison with other
hESC lines were identified using hypergeometric enrichment
analysis. Significant p-values indicate enrichment of use of the cell
lines indicated in the column headers. We observe a highly
enriched usage of the formerly NIH approved hESC lines in the
US both before and after policy changes in 2009. This pattern is
repeated in CIRM funded studies. We note a trend in the CIRM
subset towards an increased number of studies using exclusively
non eligible lines (i. e. other lines than the formerly approved NIH
hESC lines). indicates significant difference; indicates no
significant difference.
(DOCX)
Table S4 Characteristics of the seven hESC lines
highlighted in Fig. 2C and D.
(DOCX)
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